A
Aligos Therapeutics, Inc. (ALGS)
NCM – Real Time Price. Currency in USD
6.66
-0.38 (-5.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.57
-0.09 (-1.35%)
After-hours: Mar 27, 2026, 7:50 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
6.66
-0.38 (-5.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.57
-0.09 (-1.35%)
After-hours: Mar 27, 2026, 7:50 PM EDT
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. David B. Smith Ph.D. | Executive VP & Head of Chemical Operations |
| Dr. Julian A. Symons DPHIL | Executive VP & Chief Scientific Officer |
| Dr. Kieron Wesson Ph.D. | Vice President & Head of Chemistry Manufacturing Controls |
| Dr. Lawrence M. Blatt MBA, Ph.D. | CEO, President & Chairman of the Board |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President & Chief Development Officer |
| Dr. Tse-I Lin Ph.D. | Senior VP of Early Compound Development & Belgian Site Head |
| Mr. Nikhil Aneja | Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-05 | S-8 | d111225ds8.htm |
| 2025-11-06 | 10-Q | algs-20250930.htm |
| 2025-08-06 | 8-K | f8k_080625.htm |
| 2025-06-26 | 8-K | d98914d8k.htm |
| 2025-05-06 | 10-Q | algs-20250331.htm |
| 2025-04-28 | DEF 14A | d872638ddef14a.htm |
| 2025-04-16 | PRE 14A | d872638dpre14a.htm |
| 2025-04-01 | CORRESP | filename1.htm |
| 2025-03-27 | S-3 | d943530ds3.htm |
| 2025-03-10 | 8-K | f8k_031025.htm |
| Ms. Kristina Engeseth M.B.A. | Senior VP and Head of People & Culture |
| Ms. Laura Kavanaugh | VP & Head of Legal |
| Ms. Lesley Ann Calhoun CPA | Executive VP, CFO & COO |